Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AO-176 + Bortezomib + Dexamethasone|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AO-176||AO176|AO 176||CD47 Antibody 14 Immune Checkpoint Inhibitor 94||AO-176 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856, PMID: 31879362).|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04445701||Phase Ib/II||AO-176 AO-176 + Dexamethasone AO-176 + Bortezomib + Dexamethasone||Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma||Not yet recruiting|